Nanobiotix S.A. (NNBXF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nanobiotix S.A. (NNBXF) trades at $9.10. Nanobiotix S. A. is a clinical-stage biotechnology company focused on developing nanoparticle-based cancer therapies. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for NNBXF: NNBXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NNBXF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on NNBXF.
How is this calculated? →Nanobiotix S.A. (NNBXF) Healthcare & Pipeline Overview
Nanobiotix S.A. is a clinical-stage biotechnology firm specializing in nanoparticle-based cancer treatments, with its lead product NBTXR3 targeting a range of solid tumors. The company operates primarily in Europe and has established partnerships to expand its reach into Asian markets, addressing a critical need for improved cancer therapies.
What Is the Investment Thesis for NNBXF?
Nanobiotix presents a notable research candidate within the biotechnology sector, driven by its innovative NBTXR3 nanoparticle technology designed to enhance radiotherapy. A key value driver is the potential for NBTXR3 to improve treatment outcomes across a range of solid tumors, addressing a significant unmet need in cancer therapy. The company's partnership with LianBio provides access to the rapidly growing Asian markets, offering substantial revenue growth potential. Upcoming catalysts include the progression of NBTXR3 through late-stage clinical trials and potential regulatory approvals in Europe and Asia. However, potential risks include clinical trial setbacks, regulatory hurdles, and competition from established cancer therapies. With a current P/E ratio of -25.85 and a negative profit margin of -899.7%, the company's financial performance is heavily reliant on the successful commercialization of NBTXR3.
Based on FMP financials and quantitative analysis
NNBXF Key Highlights
Lead product candidate NBTXR3 targets multiple solid tumors, including soft tissue sarcoma, head and neck cancers, and liver cancers.
- Partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
- Gross margin of 100.0% indicates strong potential profitability upon commercialization, although current profit margin is -899.7%.
- Clinical-stage company focused on nanotechnology-based cancer therapies.
- Headquartered in Paris, France, with a global strategy for cancer treatment innovation.
Who Are NNBXF's Competitors?
NNBXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRTX Mirati Therapeutics, Inc. | $58.70 | -0.17% | $4.12B | 53 |
| ARRY Array Technologies, Inc. | $4.71 | -4.27% | $725M | — |
| CRSP CRISPR Therapeutics AG | $58.90 | -1.52% | $5.68B | 44 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
| RPRX Royalty Pharma plc | $60.58 | -1.86% | $26.9B | 75 |
| INCY Incyte Corporation | $127.80 | -0.53% | $25.9B | 99 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NNBXF's Key Strengths?
Innovative nanoparticle technology.
- Clinical data supporting the efficacy of NBTXR3.
- Partnership with LianBio for Asian market access.
- Experienced management team.
What Are NNBXF's Weaknesses?
Limited commercialization experience.
- Reliance on the success of NBTXR3.
- Negative profit margin.
- High research and development costs.
What Could Drive NNBXF Stock Higher?
Publication of clinical trial results for NBTXR3 in various cancer types.
- Potential regulatory approvals for NBTXR3 in Europe and Asia.
- Expansion of clinical trials to new therapeutic areas and geographic regions.
- Development of new nanoparticle-based therapies.
- Partnership discussions with pharmaceutical companies for commercialization.
What Are the Key Risks for NNBXF?
Clinical trial setbacks or failures.
- Regulatory hurdles and delays.
- Competition from established cancer therapies.
- High research and development costs.
- Dependence on the success of NBTXR3.
What Are the Growth Opportunities for NNBXF?
- Expansion into New Therapeutic Areas: Nanobiotix has the opportunity to expand the application of NBTXR3 to additional cancer types beyond its current focus. The global market for cancer therapies is vast, with specific segments like lung cancer and breast cancer representing significant opportunities. Successful clinical trials in these new areas could drive substantial revenue growth. Timeline: Ongoing, with continuous evaluation of new clinical applications.
- Geographic Expansion: The partnership with LianBio provides a strong foothold in the Asian market. Nanobiotix can further expand its geographic reach by establishing partnerships or direct operations in other key markets, such as North America and Latin America. The global cancer therapeutics market is highly fragmented, offering numerous opportunities for geographic expansion. Timeline: Medium-term, contingent on regulatory approvals and market access strategies.
- Combination Therapies: Nanobiotix can explore the potential of combining NBTXR3 with other cancer therapies, such as immunotherapy and chemotherapy. Synergistic effects could lead to improved treatment outcomes and increased market adoption. The combination therapy market is a growing segment within the cancer therapeutics landscape. Timeline: Ongoing, with preclinical and clinical studies evaluating combination approaches.
- Strategic Acquisitions: Nanobiotix could pursue strategic acquisitions of complementary technologies or companies to expand its product portfolio and capabilities. This could include acquiring companies with expertise in drug delivery, diagnostics, or other areas relevant to cancer treatment. The biotechnology industry is characterized by frequent mergers and acquisitions, offering opportunities for strategic growth. Timeline: Long-term, dependent on available capital and strategic fit.
- Advancements in Nanoparticle Technology: Continuous innovation in nanoparticle technology can lead to improved drug delivery, targeting, and efficacy. Nanobiotix can invest in research and development to enhance the properties of NBTXR3 and develop new nanoparticle-based therapies. The nanotechnology market in healthcare is projected to grow significantly in the coming years. Timeline: Ongoing, with continuous research and development efforts.
What Are NNBXF's Competitive Advantages?
- Proprietary nanoparticle technology with patent protection.
- Clinical data demonstrating the efficacy of NBTXR3.
- Partnership with LianBio for access to the Asian market.
- Expertise in nanotechnology and cancer therapy development.
What Does NNBXF Do?
Nanobiotix S.A., founded in 2003 and headquartered in Paris, France, is a clinical-stage biotechnology company pioneering the development of innovative cancer therapies using nanotechnology. The company's core technology revolves around its lead product candidate, NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles. This product is designed to enhance the effectiveness of radiotherapy by increasing the energy deposited within tumor cells, leading to improved cancer cell destruction. NBTXR3 is currently being investigated for the treatment of various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix operates primarily in Europe, conducting clinical trials and seeking regulatory approvals for NBTXR3. To expand its global reach, the company has partnered with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. This collaboration aims to accelerate the availability of Nanobiotix's innovative cancer therapy in key Asian markets, addressing a significant unmet need for advanced cancer treatments.
What Products and Services Does NNBXF Offer?
- Develops nanoparticle-based cancer therapies.
- Focuses on enhancing the efficacy of radiotherapy.
- Conducts clinical trials to evaluate the safety and efficacy of NBTXR3.
- Partners with other companies to expand its global reach.
- Seeks regulatory approvals for its products.
- Researches and develops new nanoparticle technologies for cancer treatment.
How Does NNBXF Make Money?
- Develops and patents nanoparticle-based cancer therapies.
- Conducts clinical trials to demonstrate the efficacy and safety of its products.
- Partners with pharmaceutical companies for commercialization and distribution.
- Generates revenue through licensing agreements and product sales.
What Industry Does NNBXF Operate In?
Nanobiotix operates within the biotechnology industry, which is characterized by intense research and development, high regulatory hurdles, and significant market potential for innovative therapies. The cancer therapeutics market is projected to reach $286 billion by 2026, driven by an aging population and increasing cancer incidence. Nanobiotix's competitive landscape includes established pharmaceutical companies and other biotechnology firms developing novel cancer treatments. The company differentiates itself through its unique nanoparticle technology, which aims to enhance the efficacy of existing radiotherapy treatments.
Who Are NNBXF's Key Customers?
- Hospitals and cancer treatment centers.
- Oncologists and radiation oncologists.
- Patients with solid tumors.
- Pharmaceutical companies and distributors.
Company Profile
Nanobiotix S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Paris, FR. The company is led by CEO Laurent Levy. NNBXF has traded publicly since 2020.
Key Financial Metrics
Return on equity for Nanobiotix S.A. stands at 31.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -35.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.09 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.5%, the inverse of the P/E and a quick read on earnings relative to price.
NNBXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Innovative nanoparticle technology.
- Clinical data supporting the efficacy of NBTXR3.
- Partnership with LianBio for Asian market access.
- Experienced management team.
Bear Case
- Limited commercialization experience.
- Reliance on the success of NBTXR3.
- Negative profit margin.
- High research and development costs.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
NNBXF Latest News
No recent news available for NNBXF.
NNBXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NNBXF.
Price Targets
Wall Street price target analysis for NNBXF.
NNBXF MoonshotScore
What does this score mean?
The MoonshotScore rates NNBXF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Laurent Levy
Chairman and CEO
Laurent Levy is the Chairman and CEO of Nanobiotix, a position he has held since co-founding the company in 2003. He has a strong background in business and technology, with a focus on developing innovative solutions for cancer treatment. Before Nanobiotix, Laurent worked in various roles in the technology and consulting industries. He holds degrees in engineering and business administration.
Track Record: Under Laurent Levy's leadership, Nanobiotix has advanced NBTXR3 from preclinical development to late-stage clinical trials. He has successfully secured partnerships with major pharmaceutical companies and raised significant capital to fund the company's research and development efforts. Key milestones include the CE marking of NBTXR3 for soft tissue sarcoma and the partnership with LianBio for the Asian market.
NNBXF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nanobiotix S.A. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Lack of regulatory oversight compared to major exchanges.
- Potential for price manipulation and fraud.
- Limited financial information and transparency.
- Higher risk of delisting or going out of business.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's patent portfolio and intellectual property.
- Check for any legal or regulatory issues.
- Monitor the company's news and press releases.
- Consult with a financial advisor before investing.
- Clinical-stage biotechnology company with a focus on cancer therapies.
- Lead product candidate NBTXR3 in clinical trials.
- Partnership with LianBio for Asian market development.
- Experienced management team.
- Presence in the biotechnology sector.
Common Questions About NNBXF (Healthcare)
What does Nanobiotix S.A. do?
Nanobiotix S.A. is a clinical-stage biotechnology company focused on developing innovative cancer therapies using nanotechnology. Its lead product candidate, NBTXR3, is designed to enhance the efficacy of radiotherapy by increasing the energy deposited within tumor cells. This approach aims to improve cancer cell destruction and treatment outcomes for patients with various solid tumors.
What do analysts say about NNBXF stock?
Analyst coverage of NNBXF is limited due to its OTC listing and clinical-stage nature. However, analysts generally view Nanobiotix's technology as promising, with the potential to improve cancer treatment outcomes. Key valuation metrics are difficult to assess at this stage, as the company is not yet generating significant revenue.
What are the main risks for NNBXF?
The main risks for NNBXF include clinical trial setbacks, regulatory hurdles, and competition from established cancer therapies. Clinical trials are inherently risky, and there is no guarantee that NBTXR3 will demonstrate the desired efficacy and safety. Regulatory approvals can be lengthy and uncertain, and delays could significantly impact the company's timeline and financial performance.
What are the key factors to evaluate for NNBXF?
Evaluate NNBXF on fundamentals, analyst consensus, and risk factors. Nanobiotix presents a notable research candidate within the biotechnology sector, driven by its innovative NBTXR3 nanoparticle technology designed to enhance radiotherapy. Not financial advice.
How frequently does NNBXF data refresh on this page?
NNBXF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NNBXF's recent stock price performance?
Nanobiotix S.A. (NNBXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative nanoparticle technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NNBXF overvalued or undervalued right now?
Nanobiotix S.A. (NNBXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NNBXF before investing?
Before investing in Nanobiotix S.A. (NNBXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage due to OTC listing.
- Financial data based on available information and may be incomplete.
- Clinical trial outcomes are uncertain.